TLR2-IN-C29

Catalog No.S6597 Synonyms: C29

For research use only.

TLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.

TLR2-IN-C29 Chemical Structure

CAS No. 363600-92-4

Selleck's TLR2-IN-C29 has been cited by 2 Publications

Purity & Quality Control

Choose Selective TLR Inhibitors

Biological Activity

Description TLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.
Targets
TLR2 [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 285.29
Formula

C16H15NO4

CAS No. 363600-92-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C=CC=C1N=CC2=C(C(=CC=C2)OC)O)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05368168 Recruiting Device: Posterior tibial nerve stimulation (PTNS) Rectal Disorders|Low Anterior Resection Syndrome|Low Anterior Resection Innovacion en Cirugía Vigo June 3 2022 Not Applicable
NCT04906044 Not yet recruiting Drug: Tilelimumab Tislelizumab|Locally Advanced Rectal Cancer|Total Neoadjuvant Treatment|PD-1 The First Hospital of Jilin University June 1 2021 Phase 1
NCT05046756 Recruiting Device: mHealth App and wearable device Colon Cancer Korea University Anam Hospital|National IT Industry Promotion Agency May 11 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy TLR2-IN-C29 | TLR2-IN-C29 supplier | purchase TLR2-IN-C29 | TLR2-IN-C29 cost | TLR2-IN-C29 manufacturer | order TLR2-IN-C29 | TLR2-IN-C29 distributor